Systemic treatment after sentinel lymph node biopsy in breast cancer: Who, what, and why?

Journal of the American College of Surgeons

Volumn 192, Issue 2, 2001, Pages 220-230

  Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; ONCOPROTEIN; PACLITAXEL; TAMOXIFEN; THIOTEPA; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG CHOICE; DRUG INDICATION; DRUG MEGADOSE; HUMAN; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; TREATMENT PLANNING;

EID: 0035133680     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(00)00775-4     Document Type: Article

References (73)

1. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study
2. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen-receptor negative tumors
3. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors
4. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer
5. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology
6. Prognostic significance of occult lymph node metastases in node-negative breast cancer
7. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up
8. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
9. Surgical resection and radiolocalization of the sentinel node in breast cancer using gamma probe
10. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
11. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
12. Mapping a pathway for axillary staging: A personal perspective on the current status of sentinel lymph node dissection for breast cancer
13. Learning sentinel node biopsy: Results of a prospective randomized trial of two techniques
14. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers
15. Technical aspects of sentinel node lymphoscintigraphy for breast cancer
16. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer
17. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer
18. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection
19. Intradermal blue dye to identify sentinel lymph node in breast cancer
20. Subareolar versus peritumoral injection for location of the sentinel lymph node
21. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye
22. The sentinel node in breast cancer: A multicenter validation study
23. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer
24. Sentinel lymph node involvement - A predictor for axillary node status with breast cancer - Has the time come?
25. Lymphatic mapping with sentinel lymph node biopsy in patients with breast cancers < 1 centimeter (T1a-T1b)
26. Lessons learned from 500 cases of lymphatic mapping for breast cancer
27. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer
28. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer?
29. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series
30. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
31. Meta-analysis of sentinel lymph node biopsy in breast cancer
32. Detection and significance of occult metastases in node-negative breast cancer
33. Incidence and impact of documented positive to negative complete conversion of axillary lymph node metastases in breast cancer patients treated with neoadjuvant chemotherapy
34. Prognostic importance of occult axillary lymph node micrometastases from breast cancers
35. Prognostic significance of cytokeratin-positive breast cancer metastases
36. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance
37. Polychemotherapy for early breast cancer: An overview of the randomized trials
38. Tamoxifen for early breast cancer: An overview of the randomized trials
39. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
40. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
41. The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node-negative patients with estrogen-receptor (ER) positive invasive breast cancer (BC): The first results from NSABP B-20
42. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 33 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
43. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles
44. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group Phase III Study
45. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group Study
46. Combination adjuvant chemotherapy for node-Positive breast cancer: Inadequacy ofa single perioperative cycle
47. A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer
48. NSABP halts B-14 trial: No benefit seen beyond 5 years of tamoxifen use
49. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
50. Putting taxanes to work in operable breast cancer: A search for selective indications from empirical studies
51. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer
52. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group
53. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment
54. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
55. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma
56. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors
57. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer
58. Is there a place for "dose-dense" weekly schedules of the taxoids?
59. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
60. Therapeutic implications of the sentinel lymph node in breast cancer
61. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer